Wednesday, August 5, 2020
Cocrystal Pharma Inc. (COCP)
Promising Preclinical Data from Coronavirus Program
Cocrystal Pharma Inc is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Coronavirus program preclinical study results are published. Cocrystal announced that animal study results of coronavirus antiviral compounds are published in Science Translational Medicine, one of the most prestigious medical journals. The publication highlights the mechanism action of the anti-viral compounds and the survival results of mice treated with these compounds. Cocrystal and Kansas State University Research Foundation (KSURF) have a license agreement. The publication highlights preclinical data of KSURF inhibitors.
Anti-viral compounds reduced lung infection and increased survival in mice. The preclinical data suggest anti-viral compounds are protease inhibitors (3CLpro inhibitors) that are essential for viral replication. The lead compound reduces lung viral load and lung pathology and also prolongs the survival of infected mice. The data also emphasizes …
Click to get the full report.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst
certification and important disclosures included in the full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.